These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26088121)

  • 21. Is There a Place for Off-Label Pharmacotherapy in Cannabis Use Disorder? A Review on Efficacy and Safety.
    Laprevote V; Schwan R; Schwitzer T; Rolland B; Thome J
    Curr Pharm Des; 2015; 21(23):3298-305. PubMed ID: 26088109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasticity of GABAB receptor in rat spinal cord detected by autoradiography.
    Malcangio M; Da Silva H; Bowery NG
    Eur J Pharmacol; 1993 Nov; 250(1):153-6. PubMed ID: 8119313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing alcohol versus baclofen withdrawal syndrome in patients treated with baclofen for alcohol use disorder.
    Rolland B; Jaillette E; Carton L; Bence C; Deheul S; Saulnier F; Bordet R; Cottencin O
    J Clin Psychopharmacol; 2014 Feb; 34(1):153-6. PubMed ID: 24346755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System.
    Hulse G; Kelty E; Hood S; Norman A; Basso MR; Reece AS
    Curr Pharm Des; 2015; 21(23):3325-42. PubMed ID: 26088116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and Evaluation of a New
    Naik R; Valentine H; Dannals RF; Wong DF; Horti AG
    ACS Chem Neurosci; 2018 Jun; 9(6):1453-1461. PubMed ID: 29498831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Editorial: Off-label Treatments for Mental Health: Inappropriate or Unavoidable? A Special Issue to Help Get Through the Maze.
    Rolland B; Amad A
    Curr Pharm Des; 2015; 21(23):3274-5. PubMed ID: 26238988
    [No Abstract]   [Full Text] [Related]  

  • 27. The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial.
    Hauser P; Fuller B; Ho SB; Thuras P; Kern S; Dieperink E
    Addiction; 2017 Jul; 112(7):1173-1183. PubMed ID: 28192622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of CA1 GABA
    Ebrahimi-Ghiri M; Rostampour M; Jamshidi-Mehr M; Nasehi M; Zarrindast MR
    Brain Res; 2018 Jan; 1678():164-173. PubMed ID: 29038006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GABAB receptors inhibit low-voltage activated and high-voltage activated Ca(2+) channels in sensory neurons via distinct mechanisms.
    Huang D; Huang S; Peers C; Du X; Zhang H; Gamper N
    Biochem Biophys Res Commun; 2015 Sep; 465(2):188-93. PubMed ID: 26239659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
    Froestl W; Mickel SJ; Hall RG; von Sprecher G; Strub D; Baumann PA; Brugger F; Gentsch C; Jaekel J; Olpe HR
    J Med Chem; 1995 Aug; 38(17):3297-312. PubMed ID: 7650684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baclofen for the treatment of alcohol dependence.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2012 Oct; 50(10):11-4. PubMed ID: 22998536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologically distinct GABAB receptors that mediate inhibition of GABA and glutamate release in human neocortex.
    Bonanno G; Fassio A; Schmid G; Severi P; Sala R; Raiteri M
    Br J Pharmacol; 1997 Jan; 120(1):60-4. PubMed ID: 9117099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety.
    Litten RZ; Wilford BB; Falk DE; Ryan ML; Fertig JB
    Subst Abus; 2016; 37(2):286-98. PubMed ID: 26928397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic baclofen desensitizes GABA(B)-mediated G-protein activation and stimulates phosphorylation of kinases in mesocorticolimbic rat brain.
    Keegan BM; Beveridge TJ; Pezor JJ; Xiao R; Sexton T; Childers SR; Howlett AC
    Neuropharmacology; 2015 Aug; 95():492-502. PubMed ID: 25724082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GABA Receptors: Pharmacological Potential and Pitfalls.
    Jembrek MJ; Vlainic J
    Curr Pharm Des; 2015; 21(34):4943-59. PubMed ID: 26365137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro and in vivo pharmacological characterization of SSD114, a novel GABAB positive allosteric modulator.
    Porcu A; Lobina C; Giunta D; Solinas M; Mugnaini C; Castelli MP
    Eur J Pharmacol; 2016 Nov; 791():115-123. PubMed ID: 27578262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of GABAB receptor agonists and antagonists on glycemia regulation in mice.
    Bonaventura MM; Crivello M; Ferreira ML; Repetto M; Cymeryng C; Libertun C; Lux-Lantos VA
    Eur J Pharmacol; 2012 Feb; 677(1-3):188-96. PubMed ID: 22210053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GABAergic medications for treating alcohol dependence.
    Caputo F; Vignoli T; Francini S; Stoppo M; Bernardi M
    J Clin Psychopharmacol; 2007 Oct; 27(5):539-40; author reply 540-2. PubMed ID: 17873704
    [No Abstract]   [Full Text] [Related]  

  • 39. A GABA(B) mystery: the search for pharmacologically distinct GABA(B) receptors.
    Enna SJ
    Mol Interv; 2001 Oct; 1(4):208-18. PubMed ID: 14993343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo effectiveness of CGP7930, a positive allosteric modulator of the GABAB receptor.
    Carai MA; Colombo G; Froestl W; Gessa GL
    Eur J Pharmacol; 2004 Nov; 504(3):213-6. PubMed ID: 15541424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.